The role of abuse-deterrent formulations in countering opioid misuse and abuse

被引:7
|
作者
Nguyen, V. [1 ]
Raffa, R. B. [1 ]
Taylor, R. [2 ]
Pergolizzi, J. V., Jr. [3 ,4 ,5 ]
机构
[1] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA
[2] NEMA Res, Bonita Springs, FL USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[4] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19122 USA
[5] Assoc Chron Pain Patients, Houston, TX USA
关键词
abuse; abuse-deterrent formulation; opioids; pain management; HYDROCHLORIDE; RESISTANT; CROSSOVER; THERAPY; TABLETS; ROUTES; IMPACT; SAFETY; SAMPLE; RISKS;
D O I
10.1111/jcpt.12337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objective: Pain is a prevalent, and due to the ageing population, increasing medical problem. Opioids are frequently prescribed to meet the unmet medical need. Unfortunately, with the increase in the legitimate use of opioids, there has been a corresponding increase in abuse. A practical way to retain the pain relief afforded by opioids while decreasing opportunities for abuse is to make it more difficult to extract the opioid from the product or to make it less desirable to do so by designing an abuse-deterrent formulation ( ADF). We provide a brief overview of the strategies and early evidence related to opioid ADFs. Methods: Published and unpublished literature, websites, and other sources were searched for current opioid formulation options, including immediate-release and extended-release products. Each was summarized, reviewed and assessed. Results: The strategies that have been used to design the current opioid ADFs involve one or more of four approaches: a physical barrier; incorporation of an opioid receptor antagonist (e.g. naloxone) that self-limits opioid action when taken in excess amount; inclusion of a noxious agent that is released during inappropriate use; or a pro-drug. What is new and conclusions: Legitimate use of opioid analgesics carries with it certain risks, including the risk of abuse. The new ADFs utilize four major strategies and provide innovative additions to the armamentarium. They likely will become an important part of a comprehensive approach to limiting, although not eliminating, opioid misuse and abuse.
引用
下载
收藏
页码:629 / 634
页数:6
相关论文
共 50 条
  • [1] Abuse-Deterrent Opioid Formulations
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (16): : 1744 - 1745
  • [2] Abuse-deterrent Opioid Formulations
    Litman, Ronald S.
    Pagan, Olivia H.
    Cicero, Theodore J.
    ANESTHESIOLOGY, 2018, 128 (05) : 1015 - 1026
  • [3] Abuse-Deterrent Opioid Formulations
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1476): : 119 - 121
  • [4] Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics
    Tammi Schaeffer
    Journal of Medical Toxicology, 2012, 8 (4) : 400 - 407
  • [5] Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics
    Schaeffer, Tammi
    JOURNAL OF MEDICAL TOXICOLOGY, 2012, 8 (04) : 400 - 407
  • [6] Abuse-Deterrent Opioid Formulations #329
    O'Neill, Ryann
    Lor, Kimberly
    Pruskowski, Jennifer
    JOURNAL OF PALLIATIVE MEDICINE, 2017, 20 (06) : 676 - 678
  • [7] Abuse-deterrent opioid formulations: Are they a pipe dream?
    Katz N.
    Current Rheumatology Reports, 2008, 10 (1) : 11 - 18
  • [8] Update on Abuse-Resistant and Abuse-Deterrent Approaches to Opioid Formulations
    Webster, Lynn
    PAIN MEDICINE, 2009, 10 : S124 - S133
  • [9] Abuse-Deterrent and Tamper-Resistant Opioid Formulations What is their Role in Addressing Prescription Opioid Abuse?
    Schneider, Jennifer P.
    Matthews, Michele
    Jamison, Robert N.
    CNS DRUGS, 2010, 24 (10) : 805 - 810
  • [10] Are abuse-deterrent opioid formulations all they are crushed up to be?
    Nelson, Lewis S.
    ADDICTION, 2019, 114 (03) : 401 - 402